Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.64 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.64 |
| ▸ | ITGAL | P20701 | 20/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739237 | 1.00 | ITGB2 (0.64) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20617064 | 0.92 | ITGB2 (0.61) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL30153488 | 0.91 | ITGB2 (0.60) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20618441 | 0.91 | ITGB2 (0.60) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL13666955 | 0.91 | ITGB2 (0.60) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL27044184 | 0.91 | ITGB2 (0.67) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL27044019 | 0.90 | ITGB2 (0.58) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL10168718 | 0.90 | ITGB2 (0.56) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20711049 | 0.90 | ITGB2 (0.59) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL31021041 | 0.89 | ITGB2 (0.62) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114689733-A | Method for detecting related substances of sitagliptin or preparation thereof | 扬子江药业集团南京海陵药业有限公司 | 2022-07-01 | — | — | CN | claimed |
| WO-2019043724-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2-(BENZOFURAN-6-CARBONYL)-5,7-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBOXAMIDO)-3-(3-(METHYLSULFONYL)PHENYL) PROPANOIC ACID AND POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2019-03-07 | — | — | WO | claimed |
| CN-112272665-B | Process for preparing ritalst | 欧伦股份公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| EP-3645529-B1 | PROCESS FOR PREPARING LIFITEGRAST AND INTERMEDIATES THEREOF | SCINOPHARM TAIWAN LTD (TW) | 2023-11-22 | — | — | EP | disclosed |
| CN-111747941-B | Synthesis method of leflunomide | 成都惟邦药业有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023152644-A1 | PHARMACEUTICAL COMPOSITION OF LIFITEGRAST AND LOTEPREDNOL ETABONATE | ORBICULAR PHARMACEUTICAL TECHNOLOGIES PVT. LTD (IN) | 2023-08-17 | — | — | WO | disclosed |
| US-20230027871-A1 | METHOD FOR PREPARING LIFITEGRAST | YONSUNG FINE CHEMICAL CO., LTE, (KR) | 2023-01-26 | — | — | US | disclosed |
| US-20230027871-A1 | METHOD FOR PREPARING LIFITEGRAST | YONSUNG FINE CHEMICAL CO., LTE, (KR) | 2023-01-26 | — | — | US | disclosed |
| US-11498917-B2 | Process for the preparation of lifitegrast | OLON S.P.A. (IT) | 2022-11-15 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-20230027871-A1 | METHOD FOR PREPARING LIFITEGRAST | LPXN, CSF3R, LIFR | ITGB2 561/4885ICAM1 4756/4885ITGAL 406/4885 |
| US-11498917-B2 | Process for the preparation of lifitegrast | LIFR, FLT3, F12 | ITGB2 908/4885ICAM1 4588/4885ITGAL 590/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ITGB2 8/4885ICAM1 5/4885ITGAL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.